Dupilumab for Chronic Hand Eczema: A Systematic Review and Meta-Analysis
Dermatitis® · 2026
DOI: 10.1089/derm.2024.0186 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Dermatitis®, 2026. Verfasst von Hannah R Riva und 7 weiteren Autor:innen. Beteiligte Einrichtung: From the, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, Texas, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Hand Dermatoses, Eczema. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 66 Literaturangaben.
Abstract (Originalsprache)
Chronic hand eczema (CHE) is a distressing and pervasive dermatologic condition, and effective treatment can be challenging. The novel IL-4/13 inhibitor dupilumab has shown clinical efficacy for atopic dermatitis (AD) and is being studied for CHE. PubMed database was searched for terms dupilumab and chronic hand eczema/dermatitis, including CHE subtypes (dyshidrotic, hyperkeratotic, allergic, contact, atopic, occupational, vesicular). Twenty-two study publications met inclusion and exclusion criteria for evaluation. Two multicenter prospective studies, one randomized controlled trial, two prospective observational studies, one retrospective study, nine case series, and seven case reports were included in the analysis with 374 total patients. Any partial response or complete resolution of CHE occurred in 80.3% of patients treated with dupilumab within 4–16 weeks of treatment. The patient response tended to increase throughout the duration of these studies for a significant percentage of patients, and for many it lasted beyond the study duration. Significant improvement in hand eczema severity scores and quality-of-life scores were noted. Efficacy was reported in over half of the cases of hyperkeratotic hand eczema; however, efficacy was decreased compared with relatively high consistent efficacy in other CHE subtypes such as dyshidrotic, vesicular, atopic, and contact CHE. Patients with current or previous AD had increased improvement scores compared to those without. The most common adverse effects were conjunctivitis (9.9%), herpes viral infection (1.4%), and facial erythema/dermatitis (1.3%). Dupilumab shows therapeutic efficacy in treating CHE. Further randomized controlled studies of dupilumab use in CHE subtypes are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- From the, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, Texas, USA.
- Division of Dermatology, University of Arizona, Tucson, Arizona, USA.
- Texas A&M College of Medicine, Dallas, Texas, USA.
- Dermatopathology, Epiphany Dermatology, El Paso, Texas, USA.
- Department of Dermatology, Baylor Scott & White, Temple, Texas, USA.
- Office of Research, Biostatistics and Epidemiology Consulting Lab, Texas Tech University Health Sciences Center, El Paso, Texas, USA.
ORCID-Profile: Hannah R Riva
Zitieren
APA
Riva, H. R., Yoon, T., Hendricks, A. J., Malick, H., Chisholm, C. D., Housewright, C. D., Singh, V., & Guevara, A. (2026). Dupilumab for Chronic Hand Eczema: A Systematic Review and Meta-Analysis. Dermatitis®. https://doi.org/10.1089/derm.2024.0186
Vancouver
Riva HR, Yoon T, Hendricks AJ, Malick H, Chisholm CD, Housewright CD, et al. Dupilumab for Chronic Hand Eczema: A Systematic Review and Meta-Analysis. Dermatitis®. 2026. doi:10.1089/derm.2024.0186
BibTeX
@article{Riva2026,
author = {Riva, Hannah R and Yoon, Teresa and Hendricks, Aleksi J and Malick, Hamza and Chisholm, Cary D and Housewright, Chad D and Singh, Vishwajeet and Guevara, Adrian},
title = {Dupilumab for Chronic Hand Eczema: A Systematic Review and Meta-Analysis},
journal = {Dermatitis®},
year = {2026},
doi = {10.1089/derm.2024.0186}
}
EUVIMED